PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Drug Alcohol Depend. Author manuscript; available in PMC 2011 May 1.
Published in final edited form as:
PMCID: PMC2887703
NIHMSID: NIHMS206521

OPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models

Abstract

Endogenous opioids acting at μ-opioid receptors mediate many biological functions. Pharmacological intervention at these receptors has greatly aided in the treatment of acute and chronic pain, in addition to other uses. However, the development of tolerance and dependence has made it difficult to adequately prescribe these therapeutics. A common single nucleotide polymorphism (SNP), A118G, in the μ-opioid receptor gene can affect opioid function and, consequently, has been suggested to contribute to individual variability in pain management and drug addiction. Investigation into the role of A118G in human disease and treatment response has generated a large number of association studies across various disease states as well as physiological responses. However, characterizing the functional consequences of this SNP and establishing if it causes or contributes to disease phenotypes have been significant challenges. In this manuscript, we will review a number of association studies as well as investigations of the functional impact of this gene variant. In addition, we will describe a novel mouse model that was generated to recapitulate this SNP in mice. Evaluation of models that incorporate known human genetic variants into a tractable system, like the mouse, will facilitate the understanding of discrete contributions of SNPs to human disease.

Keywords: alcohol, morphine, analgesia, dependence, pain, stress

1. Introduction

The opioid system plays a role in diverse biological functions, including reward, analgesia, and stress responsivity (Kreek and Koob, 1998; Vaccarino and Kastin, 2000). Therapeutically, opioids are commonly prescribed for their effective analgesic properties. However, the response to treatments varies widely between individuals leaving many people taking the wrong dose, experiencing unbearable side effects, or receiving inadequate therapy. Additionally, chronic use is marred by habituation, tolerance, and the development of dependence, which occur in varying degrees depending on the individual. The ability to better predict clinical outcomes based on individual differences to opioid therapeutics would greatly reduce the trial and error of finding suitable drugs and doses, and could reduce the number of patients developing drug dependence.

Individual variability results from a complex interaction of genetic and environmental factors. However, linkage disequilibrium, genome-wide association, case-controlled, and family-controlled studies have demonstrated the heritability of complex behaviors and response to drug treatments, suggesting that specific genes or alterations in genes may be responsible for the differences in behavior. Common genetic variations among individuals include single nucleotide polymorphisms (SNPs), in which a single nucleotide of the genome is altered. SNPs occur every 100-300 base pairs and account for approximately 90% of human genetic variation. The nature of the change produced by the SNP greatly depends on which nucleotide is being altered and where this change occurs in the gene. For instance, synonymous SNPs will alter the nucleotide without changing the resulting amino acid (also called a “silent mutation”). Non-synonymous SNPs are produced when the nucleotide substitution alters the resulting amino acid. Additionally, these alterations can occur in promotor, exonic, or intergenic regions and, consequently, may differentially affect transcription, processing, stability, translation, folding, transportation, and ultimately, function of the corresponding gene product.

In human populations, a commonly investigated SNP (rs1799971) occurs in exon 1 of the μ-opioid receptor gene (OPRM1), in which an adenine to guanine substitution (A118G) exchanges an asparagine for an aspartic acid at a putative N-glycosylation site (N40D). It is common in persons of European (15–30%) and Asian ancestry (40–50%), with lower prevalence in African American and Hispanic populations (1-3%) (Bergen et al., 1997; Gelernter et al., 1999; Tan et al., 2003). Despite the vast number of papers investigating the role of this SNP in human disease and drug responses, a consensus has yet to be reached on its functional consequences. The A118G SNP has been implicated in a wide variety of disorders, such as drug addiction and stress responsivity, and in treatment responses, including dependence and pain reduction; however, the mechanisms that mediate these alterations have not been determined. In this manuscript, we will review the relevant literature investigating the role of this SNP in human disease and treatment response, molecular and cellular function, and animal models that may help explain these effects. Indeed, several comprehensive reviews describe the role of pharmacogenetics, including OPRM1 and other genes, in specific disease states and treatment responses, such as alcoholism/addiction (Dick and Foroud, 2003; Enoch, 2003; Haile et al., 2008; LaForge et al., 2000; Oroszi and Goldman, 2004; Oslin et al., 2006) and pain (Kosarac et al., 2009; Lotsch et al., 2004; Skorpen et al., 2008); therefore, in this review we focus on the elucidation of the functional significance of the A118G SNP in disease states both in humans and animal models.

2. The μ-opioid receptor (MOPR)

2.1. MOPR form and function

Early investigation of the endogenous targets of opioid drugs identified three main classes of opioid receptors: μ, δ, and κ. The cloning and characterization of the opioid receptors have impacted our understanding of their gene and protein structures. The MOPR is a member of the G-protein-coupled receptor (GPCR) family and interacts with (Gi/Go) heterotrimeric G-proteins. Activation of the receptor and subsequent dissociation of the G-proteins results in the opening of G-protein-gated inwardly-rectifying K+ (GIRK) channels, inhibition of voltage-gated Ca2+ channels, and reduction of adenylyl cyclase-mediated cAMP production, all of which serve to decrease membrane potential, neuronal excitability, and neurotransmitter release in addition to affecting second-messenger systems and gene expression.

Receptor activation is achieved through binding of endogenous or exogenous ligands. β-endorphin, the peptide encoded by proopiomelanocortin (POMC), has high affinity and selectivity for the MOPR and is considered the endogenous MOPR ligand. In addition, a separate class of peptides has been proposed as μ-selective: the endomorphins (Zadina et al., 1997). The preproenkephalin gene encodes enkephalin, the endogenous ligands for the δ receptor, which has modest affinity for the MOPR as well (Raynor et al., 1994). A large number of opioids and non-opioid ligands exist for this receptor; however, those most commonly prescribed for their effective analgesic properties include morphine, codeine and oxycodone.

2.2. Genetic Variation in Human OPRM1

The human MOPR gene, OPRM1, [chromosome 6q24-q25] spans over 200kb with at least 9 exons and 19 different splice variants under the control of multiple promoters (Shabalina et al., 2009). The initial receptor subtype, MOPR-1, spanning approximately 80kb and containing 4 exons (http://genome.ucsc.edu), is abundantly expressed and has been most intensely studied. Its haplotype structure includes three large blocks with >100 polymorphisms reported (http://www.hapmap.org). In addition to the exon 1 A118G, there is in vitro functional evidence for only a few of these other polymorphisms. Two promoter polymorphisms, G–554A and A–1320G have been shown to affect transcription: G–554A decreases MOPR transcription but is extremely rare (MAF<0.001) and the A–1320G variant increases transcription, although the exact transcription factor binding to the site is unknown (MAF= 0.21) (Bayerer et al., 2007). In exon 3, G779A (R260H), G794A (R265H), and T802C (S268P) have been shown to decrease receptor coupling and signaling (Befort et al., 2001; Koch et al., 2000; Wang et al., 2001). Other OPRM1 polymorphisms that have been identified and associated with pain or opioid dependence including a short tandem (CA)n repeat (Kranzler et al., 1998), C17T (A6V), which is found primarily in African Americans (Berrettini et al., 1997), and C440G (S147C), which is extremely rare in the general population (MAF< 0.006) (Glatt et al., 2007). To date, none of these polymorphisms have in vitro evidence supporting a functional consequence.

3. A118G and drug dependence

Mesolimbic dopamine (DA) neurons in the ventral tegmental area (VTA) that project to the nucleus accumbens (NAc) are part of a well-defined pathway involved in reward processing (Nestler, 2005). GABAergic interneurons in the VTA maintain a tonic inhibition over dopaminergic neurons. Binding of β-endorphin or morphine to MOPRs on these interneurons will decrease their activity, resulting in disinhibition of the DA neurons and elevations of DA in the NAc (Johnson and North, 1992). This dopamine influx has been associated with reward and reinforcement and is believed to contribute to the development of drug dependence (Di Chiara and Imperato, 1988; Wise and Bozarth, 1985).

A number of studies have examined OPRM1 as a candidate for genetic contribution to the risk for substance dependence. The minor G118 allele has been associated with an altered susceptibility for developing drug dependence, with some studies suggesting that the SNP is a risk factor and others finding it to be protective, in addition to several studies that did not report any significant contribution of the G118 allele (Table 1). For instance, in a sample of 476 Caucasians grouped according to drug history – alcohol alone, alcohol and nicotine, or alcohol, nicotine, and illicit drug use and compared to two control groups – it was found that individuals homozygous for the A118 allele were present in greater frequency in the drug groups compared to controls. The absence of the G118 allele in the drug groups suggested it was protective against developing drug dependence (Schinka et al., 2002). Alternatively, in drug-dependent individuals in Eastern European and Russian populations, the G118 allele occurred more frequently (Zhang et al., 2006a). In addition, several studies using linkage disequilibrium or haplotype analysis (Crowley et al., 2003; Luo et al., 2003), case- or family-controlled studies (Franke et al., 2001; Gelernter et al., 1999; Xuei et al., 2007), or meta-analyses of past studies (Arias et al., 2006) failed to detect a significant involvement of A118G in drug dependence.

Table 1
Association studies investigating OPRM1 A118G involvement in drug dependence in humans

3.1. Alcohol

Alcohol has been shown to affect a wide variety of transmitter systems; however, the rewarding and reinforcing aspects of alcohol intake seem to be mediated by the opioid system (Gianoulakis, 2004; Oswald and Wand, 2004). Indeed, acute alcohol administration has been shown to cause β-endorphin release measured in the plasma (Gianoulakis and Barcomb, 1987) or in reward-related brain regions (Rasmussen et al., 1998). MOPRs appear critical for mediating alcohol effects as MOPR knock-out mice show reduced ethanol intake and reward (Hall et al., 2001; Roberts et al., 2000). Likewise, antagonism of the receptor by naloxone in rats (Reid et al., 1986) and naltrexone in humans (O’Malley et al., 1992; Volpicelli et al., 1992) has been shown to reduce alcohol intake.

Studies investigating alcohol-dependence specifically have reported positive associations with the A118G SNP (Bart et al., 2005; Kim et al., 2004b; Miranda et al., 2009; Nishizawa et al., 2006; Rommelspacher et al., 2001), no association (Bergen et al., 1997; Gscheidel et al., 2000; Kim et al., 2004a; Loh el et al., 2004; Sander et al., 1998), or a protective effect (Du and Wan, 2009; Town et al., 1999) in individuals possessing the G118 allele (Table 1). [For a detailed review of 12 of these clinical association studies, see (van der Zwaluw et al., 2007).].

A number of clinical studies have investigated altered effects of alcohol in individuals with the G118 allele. For instance, in a sample of 38 moderate and heavy drinkers without a history of alcohol problems or quit attempts, it was shown that G118 allele-carriers reported higher feelings of intoxication, stimulation, sedation, and happiness compared to A118 allele-carriers. Subjects carrying the G118 allele were also three times more likely to report a family history of alcohol use (Ray and Hutchison, 2004). In male heavy drinkers, G118 allele-carriers showed automatic approach tendencies for alcohol and other appetitive stimuli, but not for generally positive or negative stimuli (Wiers et al., 2009) and reported greater alcohol craving in a cue-reactivity task (van den Wildenberg et al., 2007). A recent study investigating the involvement of A118G in adolescent alcohol misuse found that a higher percentage of G118 allele-carriers tested positive for an alcohol use disorder, and that the G118 allele was associated with increased self-reports of drinking in order to enhance positive affect (Miranda et al., 2009). Functionally, G118 allele-carriers have demonstrated an increased BOLD response in fMRI in the orbitofrontal cortex, ventromedial prefrontal cortex, and striatum in response to alcohol and alcohol-related cues (Filbey et al., 2008). Additionally, a significant increase in dopamine receptor sensitivity, as measured by increases in apomorphine-induced growth hormone secretion, was found in G118 allele-carrying alcoholics following one week of alcohol abstinence (Smolka et al., 1999).

One of the more therapeutically relevant findings regarding the A118G SNP is in the treatment of alcoholism. It was discovered that individuals carrying the G118 allele were more likely to respond positively to naltrexone treatment (Oslin et al., 2003). In this study, there were 3.5 times more naltrexone-treated G118 allele-carriers, compared with A118 allele-carriers, who did not relapse to heavy drinking. There were no differences in rates of abstinence, suggesting that individuals with the G118 allele may better handle alcohol exposure without fully relapsing to heavy drinking. There were no differences between genotypes for those receiving placebo treatments, demonstrating that the benefit of the G118 allele is specific for naltrexone treatment and does not confer an enhanced ability for the individual to refrain from relapse. Subsequent studies investigating the involvement of this SNP in naltrexone response have replicated these initial findings (Anton et al., 2008; Kim et al., 2009; Oroszi et al., 2009; Oslin et al., 2003). For instance, using a haplotype-based approach, the A118G locus, and not SNPs found in the same haplotype block, contributed to the improved response to naltrexone treatment in alcohol-dependent subjects with the G118 allele (Oroszi et al., 2009). However, other studies failed to find an association between the G118 allele and an improved response to naltrexone (Arias et al., 2008; Gelernter et al., 2007; Tidey et al., 2008) or nalmefene treatment (Arias et al., 2008).

The mechanisms underlying the interaction of the A118G SNP and the potential benefits of naltrexone in alcohol dependence are unknown. It is thought that the effect of naltrexone is mediated by its ability to block the elevations in β-endorphin induced by alcohol administration, which are thought to contribute to the subsequent euphoria. Indeed, it has been shown that naltrexone has a greater propensity to block alcohol-induced highs in individuals with the G118 allele (Ray and Hutchison, 2007), which may, in part, explain the reduction in rates of relapse. In contrast, it was shown that the urge to drink following naltrexone treatment was greater in G118 allele-carriers (McGeary et al., 2006). However, it should be noted that in this study, conducted in non-treatment seekers, the urge to drink was evaluated following exposure to alcohol cues rather than alcohol administration.

Cortisol responses have also been implicated in drinking behavior. A study in non-treatment-seeking alcohol-dependent subjects found that G118 allele-carriers showed a trend towards decreased cortisol responses to stress, but elevated alcohol craving and intake following the stress (Pratt and Davidson, 2009). In animal models of addiction, discrete brain substrates have been identified for drug-, cue-, and stress-mediated reinstatement to drug-seeking behavior (Kalivas and McFarland, 2003). As such, it is possible that this SNP may confer benefits in certain situations, but could serve as a detriment (or not play a role) in others. [For additional information on alteration in stress-related responses, see section 4.2 “OPRM1 A118G and physiological response: Stress”.]

3.2. Heroin

Heroin directly stimulates MOPRs when converted to morphine in the brain and periphery. Similarly to alcohol, this results in activation of reward-related pathways, initially resulting in euphoria, but eventually leading to abuse and dependence. Studies evaluating the role of G118 allele in heroin dependence have reported positive associations (Bart et al., 2004; Drakenberg et al., 2006; Kapur et al., 2007; Szeto et al., 2001), negative associations (Bond et al., 1998; Tan et al., 2003), or no association (Glatt et al., 2007; Shi et al., 2002) (Table 1). For instance, one study found that approximately 90% of G118 allele-carriers were heroin users. Additionally, they found that preproenkephalin and preprodynorphin levels, which were reduced in heroin-dependent subjects, were even lower in G118 allele-carriers compared with A118 allele-carriers (Drakenberg et al., 2006). Shi and colleagues found that the G118 allele was associated with elevated daily intake of heroin in dependent subjects, though they did not find a significant effect of genotype and heroin dependence (Shi et al., 2002). A positive response to initial drug exposure is typically associated with continued use and abuse. In a study investigating the relationship between initial drug response and OPRM1 SNPs, the G118 allele was not associated with positive or negative subjective responses to first-time heroin use (Zhang et al., 2007), suggesting that differences in rates of dependence may not be explained by differences in initial euphoric experience.

3.3. Nicotine

The rewarding properties of nicotine are, in part, mediated by opioid transmission. For instance, it has been shown that nicotine stimulates the release of endogenous opioids in reward-related brain regions (Davenport et al., 1990; Pomerleau, 1998), blockade of MOPRs with systemic injections of naloxone blocks acute nicotine reward (Walters et al., 2005), MOPR null mutant mice do not show nicotine reward (Berrendero et al., 2002), and repeated treatment with nicotine elevates MOPR mRNA in the VTA (Walters et al., 2005). Human studies have reported an association of chromosome 6, which contains OPRM1, with nicotine dependence (Sullivan et al., 2004; Vink et al., 2004) (Table 1). Another study, however, found that the A118G SNP was not significantly associated with nicotine dependence, though it was in high linkage disequilibrium with haplotypes that did reach significance, suggesting there may be other SNPs nearby that confer an increased susceptibility for developing nicotine dependence (Zhang et al., 2006b). As in the case with alcohol, studies examining differences in response to nicotine administration have revealed some interesting associations. For instance, female G118 allele-carriers report attenuated rewarding effects of nicotine (Ray et al., 2006). In a separate study, nicotine was administered following the induction of a positive or negative mood via pictures and music. Smoking was reported as more rewarding to A118 allele-carriers when in a negative mood than it was for those with the G118 allele, suggesting that the A118 allele-carriers may respond more to the mood-enhancing properties of nicotine (Perkins et al., 2008). Accordingly, increases in cerebral blood flow to brain regions associated with cigarette craving were detected in smokers with the A118 allele compared to the G118 allele (Wang et al., 2008).

Consistent with alcohol studies, the A118G SNP may better predict treatment outcomes and relapse rates for those attempting to quit smoking rather than predict the susceptibility for developing nicotine dependence. Lerman and colleagues have shown that smokers with the G118 allele are significantly less likely to relapse and report fewer abstinence symptoms than smokers homozygous for the A118 allele (Lerman et al., 2004). A group in the UK reported that female G118 allele-carriers had significantly higher quit rates than female A118 allele-carriers; while the reverse was true for males (Munafo et al., 2007). It should be noted, however, that this study obtained DNA from only 50% of subjects, raising the possibility of ascertainment bias. This evidence supporting the role of the G118 allele in dependence phenotypes, such as liking and craving in chronic smokers, is more robust than evidence for association with the development of nicotine dependence.

3.4. Methamphetamine

The effects of methamphetamine (MA), which are predominantly mediated by dopaminergic and serotonergic systems, may also involve the endogenous opioid systems. Indeed, work in animals has shown that naloxone administration can block behavioral sensitization to repeated MA exposure (Chiu et al., 2005). However, the few studies investigating the effect of the A118G SNP in MA dependence failed to find an association (Ide et al., 2004; Ide et al., 2006) (Table 1).

4. A118G and physiological response

4.1. Pain and analgesia

The relationship between altered pain thresholds and analgesic responses to opioid administration for the A118G SNP has been well characterized. In a variety of populations, the G118 allele has been associated with elevated pain responses and decreased pain thresholds (Sia et al., 2008; Tan et al., 2009) and a reduced response to morphine or other opioids for patients receiving treatment for post-operative or chronic pain (Campa et al., 2008; Chou et al., 2006a; Chou et al., 2006b; Coulbault et al., 2006; Fillingim et al., 2005; Hayashida et al., 2008; Janicki et al., 2006; Klepstad et al., 2004; Landau et al., 2008; Oertel et al., 2006; Reyes-Gibby et al., 2007; Sia et al., 2008; Tan et al., 2009) (Table 2). Additionally, in healthy volunteers carrying the G118 allele, higher concentrations of alfentanil, an opioid analgesic, were required for pain relief following electrical pain stimulation (Oertel et al., 2006); of interest, this dose did not increase respiratory depression, suggesting it may be safe to give a higher dose of opioid analgesics to patients that carry the G118 allele. Other studies, however, have reported divergent results, showing that G118 was associated with reduced pain responses. For instance, in healthy volunteers receiving different experimental pain procedures, the G118 allele was associated with reduced pain responses to pressure (Fillingim et al., 2005). Additionally, males carrying the G118 allele rated thermal pain lower than those carrying the A118 allele. However, the G118 allele-carrying females reported higher pain scores following this thermal pain administration, consistent with previous literature demonstrating elevated pain responses (Fillingim et al., 2005).

Table 2
Association studies investigating OPRM1 A118G in pain experience and opioid-mediated analgesia

Morphine-6β-glucuronide (M6G) is an active metabolite of morphine that has a greater analgesic potency but a reduced potency in affecting respiratory depression (Mantione et al., 2005). In G118 allele-carrying subjects, there was a reduced potency of M6G in eliciting an analgesic response, though there was no difference in M6G-induced respiratory depression (Romberg et al., 2005). A reduction in M6G-induced miosis was also found in G118 allele-carriers (Lotsch et al., 2002).

MOPRs also play a role in social pain, described as the feelings that result from social rejection, separation, or loss. Accordingly, the G118 allele was associated with increased self-reported sensitivity to rejection (Way et al., 2009). Subsequent fMRI measurement of neural responses in these individuals found greater activation in the dorsal anterior cingulate cortex and anterior insula while experiencing social rejection, suggesting a decrease in MOPR inhibitory modulation in G118 allele-carriers. These brain regions are associated with both physical and social pain (Eisenberger and Lieberman, 2004). Together, these data support a loss of function of the MOPR in individuals harboring the G118 allele in some, but not all, responses mediated by the same compounds.

4.2. Stress response

Activation of the hypothalamic-pituitary-adrenal (HPA) axis plays an integral role in responses to stress. Following a stressor, corticotropin-releasing factor (CRF) is released from the paraventricular nucleus (PVN) of the hypothalamus, stimulating POMC synthesis in the pituitary and the release of two POMC metabolites: adrenocorticotropic hormone (ACTH) and β-endorphin. Acting on the adrenal glands, ACTH stimulates the release of glucocorticoids (cortisol in primates and corticosterone in rodents; CORT), which can then have many central and peripheral effects. MOPRs located on CRF neurons in the PVN serve to tonically inhibit HPA axis stimulation; thus, differences in endogenous opioid transmission or receptor activity can alter basal CORT levels or stress-mediated CORT responses. Just as genetic differences can affect response to drugs (pharmacogenetics), alterations in responses to an individual’s own biologically active compounds (physiogenetics) are influenced by genetic differences (Kreek and LaForge, 2007). Indeed, individuals with the G118 allele have baseline elevations in CORT levels (Bart et al., 2006; Hernandez-Avila et al., 2003). Several studies have shown that the CORT-response to a behavioral stressor is lower in G118 allele-carriers (Chong et al., 2006; Pratt and Davidson, 2009).

In contrast, a greater CORT response has been observed in G118 allele-carriers following a naloxone challenge, which may suggest an elevated tonic inhibition of CRF by β-endorphin (Chong et al., 2006; Hernandez-Avila et al., 2007; Hernandez-Avila et al., 2003). Interestingly, one of these studies found population-specific effects in which G118 allele-carriers of European descent displayed elevations in CORT responses to naloxone, while G118 allele-carriers of East Asian descent did not (Hernandez-Avila et al., 2007). These population-specific differences could suggest that the A118G SNP is in high linkage disequilibrium (LD) with other SNPs that may mediate the observed alterations.

5. Functional relevance of A118G

Most studies to date have examined the functional consequences of this SNP in vitro using various cell culture systems. Initial studies identified an elevated binding affinity of β-endorphin, but not exogenous ligands, in the G118 variant to 3-fold higher than that of the A118 in AV-12 cells stably expressing the human MOPR (hMOPR) variants (Bond et al., 1998). Additionally, β-endorphin was found to be three times more potent in activating GIRK channels in Xenopus oocytes injected with in vitro transcribed mRNAs for the A118 or G118 variants (Bond et al., 1998). Together, these data suggested a gain-of-function of the MOPR as a consequence of the A118G point mutation. However, subsequent studies using other cell culture systems – COS cells (Simian fibroblasts) (Befort et al., 2001) or HEK 293 cells (Human embryonic kidney) (Beyer et al., 2004) – were less conclusive with regard to this altered function of the G118 allele. Another consequence of MOPR activation, Ca2+ inhibition, was investigated using rat sympathetic superior ganglion (SCG) neurons expressing either the A118 or G118 variant of the hMOPR. In these studies, the potencies of both DAMGO- and morphine-mediated Ca2+ current inhibition (but not morphine-6-glucuronide or endomorphin I) were increased in SCG neurons expressing the G118 variant (Margas et al., 2007), again suggesting enhanced response for some but not all opioid compounds.

A human post-mortem study examined allele-specific mRNA expression from heterozygous individuals with the A118G polymorphism and found significant reductions in mRNA transcribed from the G118 allele. Additionally, the authors transiently expressed both variants of the MOPR in CHO cells and showed a reduction in mRNA and protein expression with the G118 allele (Zhang et al., 2005). The mechanisms underlying the decrease in expression is unclear. As the mutation occurs in a coding region, rather than a promotor, it might seem unlikely that transcription would be affected. However, using in silico tools (bioinformatics), it has been proposed that the A118G SNP may inactivate three transcription factor binding sites while creating two new ones, including a p53 site (Pang et al., 2009), suggesting that cis-acting factors could explain the alterations in expression. While transcriptional regulation using exonic sequence is rare, some examples do exist. Using Mfold technology, in which theoretical mRNA folding can be evaluated for different sequences, it was shown that the G118 variant demonstrated altered folding compared to other permutations which could affect mRNA stability (Johnson et al., 2008; Zhang et al., 2005).

Further evidence for a decrease in MOPR expression was demonstrated by studies showing a reduction in Bmax, indicative of a lower receptor number, following [3H]-DAMGO binding using both transient and stable expression of MOPR in AV-12 and HEK293 cells (Kroslak et al., 2007). Additionally, there was a decrease in agonist-mediated cAMP signaling for morphine, methadone, and DAMGO, but not β-endorphin, using stable expression in the two lines; this alteration in cAMP signaling was not seen in cell lines transiently expressing the receptor (Kroslak et al., 2007). Another study using HEK293 cells stably expressing the hMOPR also found a decrease in Bmax using DAMGO binding in the G118 variant, though they did not find alterations in binding affinity or signal transduction (Beyer et al., 2004). Conversely, a recent study investigating MOPR expression, binding, and signaling in post mortem human tissue from G118 allele-carriers found decreased agonist-induced receptor signaling efficacy in tissue from secondary somatosensory cortex, but not thalamus. However, there were no alterations in receptor expression or binding affinity (Oertel et al., 2009). Together, studies demonstrating that the G118 variant results in significantly reduced levels of MOPR expression and/or signaling suggest a loss-of-function of the mutation, while others reporting an increase in affinity and signaling suggest a gain-of-function.

6. Species-specific SNPs in OPRM1: Spontaneous and generated

6.1. Monkey orthologue (C77G)

Non-human primate research has been invaluable in the study of human disease and behavior. A conserved SNP, in which a cystine is replaced by a guanine at position 77 (C77G) resulting in a substitution of arginine with proline (R26P), occurs in the N-terminal arm of the monkey orthologue OPRM1 and has been suggested to be comparable to the A118G SNP (Miller et al., 2004). In this initial characterization of 32 male and female macaques, 44% were homozygous for the C77-allele, 50% heterozygous, and 6% homozygous for the G77 allele. It was demonstrated that monkeys possessing the minor allele (G77), had lower CORT levels both at baseline and following dexamethasone suppression and subsequent ACTH challenge. In addition to lower CORT levels, the G77 allele was associated with an increase in aggression threat, which is the early communicative aspect of aggression occurring prior to actual physical actions. By expressing these receptor-coding regions in HEK-293, the authors were able to identify an elevated affinity of the G77 allele for β-endorphin (~3.5 fold), but not exogenous ligands, similarly to original in vitro work in the A118G SNP (Bond et al., 1998). Subsequent studies have shown an increase in attachment behavior in G77 allele-carrying infants, who displayed increased distress vocalization during protracted periods of mother-infant separation and increased maternal contact during mother-infant reunion (Barr et al., 2008), possibly reflecting increased attachment reward through enhanced β-endorphin function. However, in light of the recent reports of increased social pain associated with the G118 allele (Way et al., 2009), an alternate explanation could be that the infants carrying the G118 allele had a greater sensitivity to maternal rejection, possibly through reduced MOPR function in the neocortex.

A haplotype containing the C77G SNP was shown to result in an increase in MOPR mRNA expression (Vallender et al., 2008). Though the human A118G SNP has been shown to reduce mRNA expression rather than increase it, this serves as further evidence that coding region SNPs may alter mRNA production, folding, or stability. Interestingly, in studying alcohol consumption in these macaques, a sex × genotype interaction was found, in which male carriers of the G77 allele showed elevated ethanol preference and consumption (Barr et al., 2007). In a subsequent study, macaques carrying the G77 allele showed both enhanced alcohol preferences following vehicle administration and greater reductions of alcohol preference following naltrexone administration (Barr et al., 2010).

6.2. Knock-in mouse model (A112G)

Despite information gained from human post mortem tissues, a full understanding of the OPRM1 A118G polymorphism requires extensive biochemical characterization aligned with behavioral analysis, which is not feasible in human subjects. The mouse is a tractable model system to study behavioral effects of this SNP while at the same time allowing for detailed molecular and biochemical analysis in vivo. Homologous recombination technology can now be used to generate point mutations in mice for those genes in which human SNPs have been identified. This approach, however, has not been fully utilized due in part to the labor-intensive procedures involved in building the complex targeting vectors required. Recent advances and the availability of bacterial artificial chromosome (BAC) vectors have streamlined this process, making the use of knock-in mice a natural progression to investigate human disease. To gain insight into the role of the A118G variant in humans, we have generated the equivalent point mutation in mice, A112G, which alters the same amino acid coding from an asparagine to aspartic acid at position 38 (Asn38Asp; N38D), eliminating an N-linked glycosylation site.

A number of molecular, biochemical, and behavioral alterations that resemble those previously identified in human and in vitro studies have been identified in G112 mice (Mague et al., 2009). For instance, the presence of the G112 allele results in decreased MOPR mRNA and protein expression. This decrease in receptor expression was also seen using [3H]-DAMGO binding, though there were no alterations in affinity for β-endorphin or exogenous ligands (morphine, DAMGO, or naloxone). Mice with the G112 allele showed only a modest elevation in locomotor activity following acute morphine administration and failed to develop sensitization to repeated, intermittent injections. Similarly, G112 mice had reduced morphine-induced antinociceptive responses, though they showed similar signs of tolerance following repeated treatments. A sex × genotype interaction was found in measures of hedonia: female G112-carriers did not display a preference for morphine-associated environments nor did they demonstrate an aversion to environments associated with naloxone-precipitated withdrawal.

Since the A112G SNP alters MOPR expression, some of the behavioral outcomes could be explained by the reduction in protein levels. Indeed, studies investigating opioid responses in MOPR knockout heterozygous mice have found similar reductions in morphine-mediated antinociception using tail flick and hot plate tests (Sora et al., 1997) and sex-specific decreases in alcohol reward using voluntary ethanol consumption and place-conditioning paradigms (Hall et al., 2001). However, these sex-specific differences in ethanol reward were due in large part to elevated responses in wild type female mice compared to wild type male mice, with little differences reported between male and female heterozygous mice. Indeed in wild type male mice, no ethanol preference was observed; therefore, it is difficult to assess whether or not heterozygous MOPR knockout males displayed ethanol reward deficits. In addition to reducing expression levels, it should be emphasized that one consequence of the A112G knockin mouse (and the A118G SNP) is the deletion of an N-linked glycosylation site. Glycosylation plays a role in receptor sorting, expression, trafficking, ligand binding, and signal transduction (Fan et al., 1997; Rathz et al., 2002; Zhang et al., 2001); alterations in these processes could affect MOPR function in ways distinct from protein level changes.

The A112G mouse model, similarly to the C77G non-human primate model, possesses analogous phenotypes as those reported in human studies and identifies new behaviors that have not been investigated. The A112G mouse model seems to replicate the loss-of-function phenotypes (e.g., decreased expression, reduced morphine-mediated antinociception, decreased hedonic reward), though it should be noted that decreases are not present in all morphine-mediated behaviors, suggesting that the alterations are dependent on other factors, including brain region, other neurotransmitter systems, and sex. Future work will investigate the effects of the A112G SNP on alcohol consumption and stress responsivity to evaluate whether or not these animals display any gain-of-function phenotypes as suggested by human studies.

7. Conclusion

The A118G SNP in the human OPRM1 gene has been studied intensely and implicated in a variety of disease states and treatment responses. In particular, alterations in receptor function resulting from this SNP are believed to contribute to the susceptibility for developing drug dependence. The strongest evidence for a beneficial effect of the A118G polymorphism stems from studies evaluating the response to naltrexone for alcohol and nicotine consumption, highlighting the importance of pharmacogenetics when devising treatment options to determine who may be more likely to benefit from a given therapy. In addition to choosing treatment options, understanding the mechanisms underlying these beneficial effects may allow us to develop therapies for individuals with the common A118 allele.

As acute overdose and long-term dependence are concerns when treating acute and chronic pain with opiates, it is important to minimize the dose prescribed in order to reduce the amount of drug the patient receives. The evidence showing a diminished response to opioid-mediated analgesia in G118 subjects illustrates the need for utilizing pharmacogenetics when developing treatment options. For instance, though G118 patients require higher doses of opioids for pain management, it has also been shown that they may be more resistant to the respiratory depressive effects of alfentanil than A118 allele-carrying individuals, suggesting that there may be less risk in providing these higher doses (Oertel et al., 2006).

Cross-species experiments allow investigators to validate both pharmacogenetic and physiogenetic phenotypes. Despite the potential of this approach to yield valuable information for treatment development, few mouse/human comparisons of SNPs have been reported. The derivation of the Oprm1 A112G mouse will allow for such studies to investigate aspects of this SNP that have yet to be delineated in human populations. We know from human studies that the OPRM1 A118G SNP can impact the response to treatment; however, we have learned from studies in mice that this SNP also influences sex-specific drug behaviors, differences that have been largely ignored in human association studies. Moreover, we anticipate that this mouse model may assist in drug design to generate effective analgesics and other opioid therapies without the risk of abuse liability.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Terms:

Human SNP: A118G = Asn40Asp = N40D

Mouse SNP: A112G = Asn38Asp = N38D

Rhesus Macaque SNP: C77G = Pro26Arg = P26R

References

  • Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, Goldman D. An Evaluation of Mu-Opioid Receptor (Oprm1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (Combine) Study. Arch Gen Psychiatry. 2008;65:135–144. [PMC free article] [PubMed]
  • Arias A, Feinn R, Kranzler HR. Association of an Asn40asp (A118g) Polymorphism in the Mu-Opioid Receptor Gene with Substance Dependence: A Meta-Analysis. Drug Alcohol Depend. 2006;83:262–268. [PubMed]
  • Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Makela R, Kranzler HR. Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. Alcohol Clin Exp Res. 2008;32:1159–1166. [PMC free article] [PubMed]
  • Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ, Heilig M. Suppression of Alcohol Preference by Naltrexone in the Rhesus Macaque: A Critical Role of Genetic Variation at the Mu-Opioid Receptor Gene Locus. Biol Psychiatry. 2009;67:78–80. [PMC free article] [PubMed]
  • Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ, Higley JD, Heilig M. Association of a Functional Polymorphism in the Mu-Opioid Receptor Gene with Alcohol Response and Consumption in Male Rhesus Macaques. Arch Gen Psychiatry. 2007;64:369–376. [PubMed]
  • Barr CS, Schwandt ML, Lindell SG, Higley JD, Maestripieri D, Goldman D, Suomi SJ, Heilig M. Variation at the Mu-Opioid Receptor Gene (Oprm1) Influences Attachment Behavior in Infant Primates. Proc Natl Acad Sci U S A. 2008;105:5277–5281. [PubMed]
  • Bart G, Heilig M, LaForge KS, Pollak L, Leal SM, Ott J, Kreek MJ. Substantial Attributable Risk Related to a Functional Mu-Opioid Receptor Gene Polymorphism in Association with Heroin Addiction in Central Sweden. Mol Psychiatry. 2004;9:547–549. [PubMed]
  • Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M. Increased Attributable Risk Related to a Functional Mu-Opioid Receptor Gene Polymorphism in Association with Alcohol Dependence in Central Sweden. Neuropsychopharmacology. 2005;30:417–422. [PubMed]
  • Bart G, LaForge KS, Borg L, Lilly C, Ho A, Kreek MJ. Altered Levels of Basal Cortisol in Healthy Subjects with a 118g Allele in Exon 1 of the Mu Opioid Receptor Gene. Neuropsychopharmacology. 2006;31:2313–2317. [PubMed]
  • Bayerer B, Stamer U, Hoeft A, Stuber F. Genomic Variations and Transcriptional Regulation of the Human Mu-Opioid Receptor Gene. Eur J Pain. 2007;11:421–427. [PubMed]
  • Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A Single Nucleotide Polymorphic Mutation in the Human Mu-Opioid Receptor Severely Impairs Receptor Signaling. J Biol Chem. 2001;276:3130–3137. [PubMed]
  • Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D. Mu Opioid Receptor Gene Variants: Lack of Association with Alcohol Dependence. Mol Psychiatry. 1997;2:490–494. [PubMed]
  • Berrendero F, Kieffer BL, Maldonado R. Attenuation of Nicotine-Induced Antinociception, Rewarding Effects, and Dependence in Mu-Opioid Receptor Knock-out Mice. J Neurosci. 2002;22:10935–10940. [PubMed]
  • Berrettini WH, Hoehe MR, Ferraro TN, DeMaria PA, Gottheil E. Human Mu Opiod Receptor Gene Polymorphisms and Vulnerability to Substance Abuse. Addiction Biol. 1997;2:303–308.
  • Beyer A, Koch T, Schroder H, Schulz S, Hollt V. Effect of the A118g Polymorphism on Binding Affinity, Potency and Agonist-Mediated Endocytosis, Desensitization, and Resensitization of the Human Mu-Opioid Receptor. J Neurochem. 2004;89:553–560. [PubMed]
  • Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single-Nucleotide Polymorphism in the Human Mu Opioid Receptor Gene Alters Beta-Endorphin Binding and Activity: Possible Implications for Opiate Addiction. Proc Natl Acad Sci U S A. 1998;95:9608–9613. [PubMed]
  • Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of Abcb1/Mdr1 and Oprm1 Gene Polymorphisms with Morphine Pain Relief. Clin Pharmacol Ther. 2008;83:559–566. [PubMed]
  • Chiu CT, Ma T, Ho IK. Attenuation of Methamphetamine-Induced Behavioral Sensitization in Mice by Systemic Administration of Naltrexone. Brain Res Bull. 2005;67:100–109. [PMC free article] [PubMed]
  • Chong RY, Oswald L, Yang X, Uhart M, Lin PI, Wand GS. The Micro-Opioid Receptor Polymorphism A118g Predicts Cortisol Responses to Naloxone and Stress. Neuropsychopharmacology. 2006;31:204–211. [PubMed]
  • Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human Opioid Receptor A118g Polymorphism Affects Intravenous Patient-Controlled Analgesia Morphine Consumption after Total Abdominal Hysterectomy. Anesthesiology. 2006a;105:334–337. [PubMed]
  • Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ. Association of Mu-Opioid Receptor Gene Polymorphism (A118g) with Variations in Morphine Consumption for Analgesia after Total Knee Arthroplasty. Acta Anaesthesiol Scand. 2006b;50:787–792. [PubMed]
  • Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Tregouet D, Descot C, Parc Y, Lienhart A, Jaillon P, Becquemont L. Environmental and Genetic Factors Associated with Morphine Response in the Postoperative Period. Clin Pharmacol Ther. 2006;79:316–324. [PubMed]
  • Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria PA, Jr., O’Brien CP, Berrettini WH, Grice DE. A Genetic Association Study of the Mu Opioid Receptor and Severe Opioid Dependence. Psychiatr Genet. 2003;13:169–173. [PubMed]
  • Davenport KE, Houdi AA, Van Loon GR. Nicotine Protects against Mu-Opioid Receptor Antagonism by Beta-Funaltrexamine: Evidence for Nicotine-Induced Release of Endogenous Opioids in Brain. Neurosci Lett. 1990;113:40–46. [PubMed]
  • Di Chiara G, Imperato A. Drugs Abused by Humans Preferentially Increase Synaptic Dopamine Concentrations in the Mesolimbic System of Freely Moving Rats. Proc Natl Acad Sci U S A. 1988;85:5274–5278. [PubMed]
  • Dick DM, Foroud T. Candidate Genes for Alcohol Dependence: A Review of Genetic Evidence from Human Studies. Alcohol Clin Exp Res. 2003;27:868–879. [PubMed]
  • Drakenberg K, Nikoshkov A, Horvath MC, Fagergren P, Gharibyan A, Saarelainen K, Rahman S, Nylander I, Bakalkin G, Rajs J, Keller E, Hurd YL. Mu Opioid Receptor A118g Polymorphism in Association with Striatal Opioid Neuropeptide Gene Expression in Heroin Abusers. Proc Natl Acad Sci U S A. 2006;103:7883–7888. [PubMed]
  • Du Y, Wan YJ. The Interaction of Reward Genes with Environmental Factors in Contribution to Alcoholism in Mexican Americans. Alcohol Clin Exp Res. 2009 [PubMed]
  • Eisenberger NI, Lieberman MD. Why Rejection Hurts: A Common Neural Alarm System for Physical and Social Pain. Trends Cogn Sci. 2004;8:294–300. [PubMed]
  • Enoch MA. Pharmacogenomics of Alcohol Response and Addiction. Am J Pharmacogenomics. 2003;3:217–232. [PubMed]
  • Fan G, Goldsmith PK, Collins R, Dunn CK, Krapcho KJ, Rogers KV, Spiegel AM. N-Linked Glycosylation of the Human Ca2+ Receptor Is Essential for Its Expression at the Cell Surface. Endocrinology. 1997;138:1916–1922. [PubMed]
  • Filbey FM, Ray L, Smolen A, Claus ED, Audette A, Hutchison KE. Differential Neural Response to Alcohol Priming and Alcohol Taste Cues Is Associated with Drd4 Vntr and Oprm1 Genotypes. Alcohol Clin Exp Res. 2008;32:1113–1123. [PMC free article] [PubMed]
  • Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM, Mogil JS, Wallace MR. The A118g Single Nucleotide Polymorphism of the Mu-Opioid Receptor Gene (Oprm1) Is Associated with Pressure Pain Sensitivity in Humans. J Pain. 2005;6:159–167. [PubMed]
  • Franke P, Wang T, Nothen MM, Knapp M, Neidt H, Albrecht S, Jahnes E, Propping P, Maier W. Nonreplication of Association between Mu-Opioid-Receptor Gene (Oprm1) A118g Polymorphism and Substance Dependence. Am J Med Genet. 2001;105:114–119. [PubMed]
  • Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH. Opioid Receptor Gene (Oprm1, Oprk1, and Oprd1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results from the Va Cooperative Study. Alcohol Clin Exp Res. 2007;31:555–563. [PubMed]
  • Gelernter J, Kranzler H, Cubells J. Genetics of Two Mu Opioid Receptor Gene (Oprm1) Exon I Polymorphisms: Population Studies, and Allele Frequencies in Alcohol- and Drug-Dependent Subjects. Mol Psychiatry. 1999;4:476–483. [PubMed]
  • Gianoulakis C. Endogenous Opioids and Addiction to Alcohol and Other Drugs of Abuse. Curr Top Med Chem. 2004;4:39–50. [PubMed]
  • Gianoulakis C, Barcomb A. Effect of Acute Ethanol in Vivo and in Vitro on the Beta-Endorphin System in the Rat. Life Sci. 1987;40:19–28. [PubMed]
  • Glatt SJ, Bousman C, Wang RS, Murthy KK, Rana BK, Lasky-Su JA, Zhu SC, Zhang R, Li J, Zhang B, Li J, Lyons MJ, Faraone SV, Tsuang MT. Evaluation of Oprm1 Variants in Heroin Dependence by Family-Based Association Testing and Meta-Analysis. Drug Alcohol Depend. 2007;90:159–165. [PMC free article] [PubMed]
  • Gscheidel N, Sander T, Wendel B, Heere P, Schmidt LG, Rommelspacher H, Hoehe MR, Samochowiec J. Five Exon 1 Variants of Mu Opioid Receptor and Vulnerability to Alcohol Dependence. Pol J Pharmacol. 2000;52:27–31. [PubMed]
  • Haile CN, Kosten TA, Kosten TR. Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates. Am J Drug Alcohol Abuse. 2008;34:355–381. [PubMed]
  • Hall FS, Sora I, Uhl GR. Ethanol Consumption and Reward Are Decreased in Mu-Opiate Receptor Knockout Mice. Psychopharmacology (Berl) 2001;154:43–49. [PubMed]
  • Hayashida M, Nagashima M, Satoh Y, Katoh R, Tagami M, Ide S, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Komatsu H, Sora I, Fukuda K, Koga H, Hanaoka K, Ikeda K. Analgesic Requirements after Major Abdominal Surgery Are Associated with Oprm1 Gene Polymorphism Genotype and Haplotype. Pharmacogenomics. 2008;9:1605–1616. [PubMed]
  • Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR. Population-Specific Effects of the Asn40asp Polymorphism at the Mu-Opioid Receptor Gene (Oprm1) on Hpa-Axis Activation. Pharmacogenet Genomics. 2007;17:1031–1038. [PubMed]
  • Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR. Association between the Cortisol Response to Opioid Blockade and the Asn40asp Polymorphism at the Mu-Opioid Receptor Locus (Oprm1) Am J Med Genet B Neuropsychiatr Genet. 2003;118B:60–65. [PubMed]
  • Ide S, Kobayashi H, Tanaka K, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Ikeda K, Sora I. Gene Polymorphisms of the Mu Opioid Receptor in Methamphetamine Abusers. Ann N Y Acad Sci. 2004;1025:316–324. [PubMed]
  • Ide S, Kobayashi H, Ujike H, Ozaki N, Sekine Y, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Iwata N, Tanaka K, Shen H, Iwahashi K, Itokawa M, Minami M, Satoh M, Ikeda K, Sora I. Linkage Disequilibrium and Association with Methamphetamine Dependence/Psychosis of Mu-Opioid Receptor Gene Polymorphisms. Pharmacogenomics J. 2006;6:179–188. [PubMed]
  • Janicki PK, Schuler G, Francis D, Bohr A, Gordin V, Jarzembowski T, Ruiz-Velasco V, Mets B. A Genetic Association Study of the Functional A118g Polymorphism of the Human Mu-Opioid Receptor Gene in Patients with Acute and Chronic Pain. Anesth Analg. 2006;103:1011–1017. [PubMed]
  • Johnson AD, Zhang Y, Papp AC, Pinsonneault JK, Lim JE, Saffen D, Dai Z, Wang D, Sadee W. Polymorphisms Affecting Gene Transcription and Mrna Processing in Pharmacogenetic Candidate Genes: Detection through Allelic Expression Imbalance in Human Target Tissues. Pharmacogenet Genomics. 2008;18:781–791. [PMC free article] [PubMed]
  • Johnson SW, North RA. Opioids Excite Dopamine Neurons by Hyperpolarization of Local Interneurons. J Neurosci. 1992;12:483–488. [PubMed]
  • Kalivas PW, McFarland K. Brain Circuitry and the Reinstatement of Cocaine-Seeking Behavior. Psychopharmacology (Berl) 2003;168:44–56. [PubMed]
  • Kapur S, Sharad S, Singh RA, Gupta AK. A118g Polymorphism in Mu Opioid Receptor Gene (Oprm1): Association with Opiate Addiction in Subjects of Indian Origin. J Integr Neurosci. 2007;6:511–522. [PubMed]
  • Kim SA, Kim JW, Song JY, Park S, Lee HJ, Chung JH. Association of Polymorphisms in Nicotinic Acetylcholine Receptor Alpha 4 Subunit Gene (Chrna4), Mu-Opioid Receptor Gene (Oprm1), and Ethanol-Metabolizing Enzyme Genes with Alcoholism in Korean Patients. Alcohol. 2004a;34:115–120. [PubMed]
  • Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW. A Micro Opioid Receptor Gene Polymorphism (A118g) and Naltrexone Treatment Response in Adherent Korean Alcohol-Dependent Patients. Psychopharmacology (Berl) 2009;201:611–618. [PubMed]
  • Kim SG, Kim CM, Kang DH, Kim YJ, Byun WT, Kim SY, Park JM, Kim MJ, Oslin DW. Association of Functional Opioid Receptor Genotypes with Alcohol Dependence in Koreans. Alcohol Clin Exp Res. 2004b;28:986–990. [PubMed]
  • Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F. The 118 a > G Polymorphism in the Human Mu-Opioid Receptor Gene May Increase Morphine Requirements in Patients with Pain Caused by Malignant Disease. Acta Anaesthesiol Scand. 2004;48:1232–1239. [PubMed]
  • Koch T, Kroslak T, Averbeck M, Mayer P, Schroder H, Raulf E, Hollt V. Allelic Variation S268p of the Human Mu-Opioid Receptor Affects Both Desensitization and G Protein Coupling. Mol Pharmacol. 2000;58:328–334. [PubMed]
  • Kosarac B, Fox AA, Collard CD. Effect of Genetic Factors on Opioid Action. Curr Opin Anaesthesiol. 2009 [PubMed]
  • Kranzler HR, Gelernter J, O’Malley S, Hernandez-Avila CA, Kaufman D. Association of Alcohol or Other Drug Dependence with Alleles of the Mu Opioid Receptor Gene (Oprm1) Alcohol Clin Exp Res. 1998;22:1359–1362. [PubMed]
  • Kreek MJ, Koob GF. Drug Dependence: Stress and Dysregulation of Brain Reward Pathways. Drug Alcohol Depend. 1998;51:23–47. [PubMed]
  • Kreek MJ, LaForge KS. Stress Responsivity, Addiction, and a Functional Variant of the Human Mu-Opioid Receptor Gene. Mol Interv. 2007;7:74–78. [PubMed]
  • Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The Single Nucleotide Polymorphism A118g Alters Functional Properties of the Human Mu Opioid Receptor. J Neurochem. 2007;103:77–87. [PubMed]
  • LaForge KS, Yuferov V, Kreek MJ. Opioid Receptor and Peptide Gene Polymorphisms: Potential Implications for Addictions. Eur J Pharmacol. 2000;410:249–268. [PubMed]
  • Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic Variability of the Mu-Opioid Receptor Influences Intrathecal Fentanyl Analgesia Requirements in Laboring Women. Pain. 2008;139:5–14. [PMC free article] [PubMed]
  • Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH. The Functional Mu Opioid Receptor (Oprm1) Asn40asp Variant Predicts Short-Term Response to Nicotine Replacement Therapy in a Clinical Trial. Pharmacogenomics J. 2004;4:184–192. [PubMed]
  • Loh el W, Fann CS, Chang YT, Chang CJ, Cheng AT. Endogenous Opioid Receptor Genes and Alcohol Dependence among Taiwanese Han. Alcohol Clin Exp Res. 2004;28:15–19. [PubMed]
  • Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The Polymorphism A118g of the Human Mu-Opioid Receptor Gene Decreases the Pupil Constrictory Effect of Morphine-6-Glucuronide but Not That of Morphine. Pharmacogenetics. 2002;12:3–9. [PubMed]
  • Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic Predictors of the Clinical Response to Opioid Analgesics: Clinical Utility and Future Perspectives. Clin Pharmacokinet. 2004;43:983–1013. [PubMed]
  • Luo X, Kranzler HR, Zhao H, Gelernter J. Haplotypes at the Oprm1 Locus Are Associated with Susceptibility to Substance Dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet. 2003;120B:97–108. [PubMed]
  • Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA. Mouse Model of Oprm1 (A118g) Polymorphism Has Sex-Specific Effects on Drug-Mediated Behavior. Proc Natl Acad Sci U S A. 2009;106:10847–10852. [PubMed]
  • Mantione KJ, Goumon Y, Esch T, Stefano GB. Morphine 6beta Glucuronide: Fortuitous Morphine Metabolite or Preferred Peripheral Regulatory Opiate? Med Sci Monit. 2005;11:MS43–46. [PubMed]
  • Margas W, Zubkoff I, Schuler HG, Janicki PK, Ruiz-Velasco V. Modulation of Ca2+ Channels by Heterologously Expressed Wild-Type and Mutant Human Micro-Opioid Receptors (Hmors) Containing the A118g Single-Nucleotide Polymorphism. J Neurophysiol. 2007;97:1058–1067. [PubMed]
  • McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R., Jr. Genetic Moderators of Naltrexone’s Effects on Alcohol Cue Reactivity. Alcohol Clin Exp Res. 2006;30:1288–1296. [PubMed]
  • Miller GM, Bendor J, Tiefenbacher S, Yang H, Novak MA, Madras BK. A Mu-Opioid Receptor Single Nucleotide Polymorphism in Rhesus Monkey: Association with Stress Response and Aggression. Mol Psychiatry. 2004;9:99–108. [PubMed]
  • Miranda R, Ray L, Justus A, Meyerson LA, Knopik VS, McGeary J, Monti PM. Initial Evidence of an Association between Oprm1 and Adolescent Alcohol Misuse. Alcohol Clin Exp Res. 2009 in press. Epub ahead of print 23 October 2009. [PubMed]
  • Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the Mu-Opioid Receptor Gene with Smoking Cessation. Pharmacogenomics J. 2007;7:353–361. [PubMed]
  • Nestler EJ. Is There a Common Molecular Pathway for Addiction? Nat Neurosci. 2005;8:1445–1449. [PubMed]
  • Nishizawa D, Han W, Hasegawa J, Ishida T, Numata Y, Sato T, Kawai A, Ikeda K. Association of Mu-Opioid Receptor Gene Polymorphism A118g with Alcohol Dependence in a Japanese Population. Neuropsychobiology. 2006;53:137–141. [PubMed]
  • O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and Coping Skills Therapy for Alcohol Dependence. A Controlled Study. Arch Gen Psychiatry. 1992;49:881–887. [PubMed]
  • Oertel BG, Kettner M, Scholich K, Renne C, Roskam B, Geisslinger G, Schmidt PH, Lotsch J. A Common Human Micro-Opioid Receptor Genetic Variant Diminishes the Receptor Signaling Efficacy in Brain Regions Processing the Sensory Information of Pain. J Biol Chem. 2009;284:6530–6535. [PubMed]
  • Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The Mu-Opioid Receptor Gene Polymorphism 118a>G Depletes Alfentanil-Induced Analgesia and Protects against Respiratory Depression in Homozygous Carriers. Pharmacogenet Genomics. 2006;16:625–636. [PubMed]
  • Oroszi G, Anton RF, O’Malley S, Swift R, Pettinati H, Couper D, Yuan Q, Goldman D. Oprm1 Asn40asp Predicts Response to Naltrexone Treatment: A Haplotype-Based Approach. Alcohol Clin Exp Res. 2009;33:383–393. [PMC free article] [PubMed]
  • Oroszi G, Goldman D. Alcoholism: Genes and Mechanisms. Pharmacogenomics. 2004;5:1037–1048. [PubMed]
  • Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O’Brien CP. A Functional Polymorphism of the Mu-Opioid Receptor Gene Is Associated with Naltrexone Response in Alcohol-Dependent Patients. Neuropsychopharmacology. 2003;28:1546–1552. [PubMed]
  • Oslin DW, Berrettini WH, O’Brien CP. Targeting Treatments for Alcohol Dependence: The Pharmacogenetics of Naltrexone. Addict Biol. 2006;11:397–403. [PubMed]
  • Oswald LM, Wand GS. Opioids and Alcoholism. Physiol Behav. 2004;81:339–358. [PubMed]
  • Pang GS, Wang J, Wang Z, Goh C, Lee CG. The G Allele of Snp E1/A118g at the Micro-Opioid Receptor Gene Locus Shows Genomic Evidence of Recent Positive Selection. Pharmacogenomics. 2009;10:1101–1109. [PubMed]
  • Perkins KA, Lerman C, Grottenthaler A, Ciccocioppo MM, Milanak M, Conklin CA, Bergen AW, Benowitz NL. Dopamine and Opioid Gene Variants Are Associated with Increased Smoking Reward and Reinforcement Owing to Negative Mood. Behav Pharmacol. 2008;19:641–649. [PMC free article] [PubMed]
  • Pomerleau OF. Endogenous Opioids and Smoking: A Review of Progress and Problems. Psychoneuroendocrinology. 1998;23:115–130. [PubMed]
  • Pratt WM, Davidson D. Role of the Hpa Axis and the A118g Polymorphism of the Mu-Opioid Receptor in Stress-Induced Drinking Behavior. Alcohol Alcohol. 2009;44:358–365. [PMC free article] [PubMed]
  • Rasmussen DD, Bryant CA, Boldt BM, Colasurdo EA, Levin N, Wilkinson CW. Acute Alcohol Effects on Opiomelanocortinergic Regulation. Alcohol Clin Exp Res. 1998;22:789–801. [PubMed]
  • Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino Acid 49 Polymorphisms of the Human Beta1-Adrenergic Receptor Affect Agonist-Promoted Trafficking. J Cardiovasc Pharmacol. 2002;39:155–160. [PubMed]
  • Ray LA, Hutchison KE. A Polymorphism of the Mu-Opioid Receptor Gene (Oprm1) and Sensitivity to the Effects of Alcohol in Humans. Alcohol Clin Exp Res. 2004;28:1789–1795. [PubMed]
  • Ray LA, Hutchison KE. Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response: A Double-Blind Placebo-Controlled Study. Arch Gen Psychiatry. 2007;64:1069–1077. [PubMed]
  • Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, Lynch KG, O’Malley S, Berrettini WH, Lerman C. Association of Oprm1 A118g Variant with the Relative Reinforcing Value of Nicotine. Psychopharmacology (Berl) 2006;188:355–363. [PubMed]
  • Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T. Pharmacological Characterization of the Cloned Kappa-, Delta-, and Mu-Opioid Receptors. Mol Pharmacol. 1994;45:330–334. [PubMed]
  • Reid LD, Czirr SA, Milano WC, Hubbell CL, Manha NA. Opioids and Intake of Alcoholic Beverages. NIDA Res Monogr. 1986;75:359–362. [PubMed]
  • Reyes-Gibby CC, Shete S, Rakvag T, Bhat SV, Skorpen F, Bruera E, Kaasa S, Klepstad P. Exploring Joint Effects of Genes and the Clinical Efficacy of Morphine for Cancer Pain: Oprm1 and Comt Gene. Pain. 2007;130:25–30. [PMC free article] [PubMed]
  • Roberts AJ, McDonald JS, Heyser CJ, Kieffer BL, Matthes HW, Koob GF, Gold LH. Mu-Opioid Receptor Knockout Mice Do Not Self-Administer Alcohol. J Pharmacol Exp Ther. 2000;293:1002–1008. [PubMed]
  • Romberg RR, Olofsen E, Bijl H, Taschner PE, Teppema LJ, Sarton EY, van Kleef JW, Dahan A. Polymorphism of Mu-Opioid Receptor Gene (Oprm1:C.118a>G) Does Not Protect against Opioid-Induced Respiratory Depression Despite Reduced Analgesic Response. Anesthesiology. 2005;102:522–530. [PubMed]
  • Rommelspacher H, Smolka M, Schmidt LG, Samochowiec J, Hoehe MR. Genetic Analysis of the Mu-Opioid Receptor in Alcohol-Dependent Individuals. Alcohol. 2001;24:129–135. [PubMed]
  • Sander T, Gscheidel N, Wendel B, Samochowiec J, Smolka M, Rommelspacher H, Schmidt LG, Hoehe MR. Human Mu-Opioid Receptor Variation and Alcohol Dependence. Alcohol Clin Exp Res. 1998;22:2108–2110. [PubMed]
  • Schinka JA, Town T, Abdullah L, Crawford FC, Ordorica PI, Francis E, Hughes P, Graves AB, Mortimer JA, Mullan M. A Functional Polymorphism within the Mu-Opioid Receptor Gene and Risk for Abuse of Alcohol and Other Substances. Mol Psychiatry. 2002;7:224–228. [PubMed]
  • Shabalina SA, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, Shibata K, Tchivileva IE, Belfer I, Mishra B, Kiselycznyk C, Wallace MR, Staud R, Spiridonov NA, Max MB, Goldman D, Fillingim RB, Maixner W, Diatchenko L. Expansion of the Human Mu-Opioid Receptor Gene Architecture: Novel Functional Variants. Hum Mol Genet. 2009;18:1037–1051. [PMC free article] [PubMed]
  • Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G. Sequence Variations in the Mu-Opioid Receptor Gene (Oprm1) Associated with Human Addiction to Heroin. Hum Mutat. 2002;19:459–460. [PubMed]
  • Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R, Teo YY, Tan EC. A118g Single Nucleotide Polymorphism of Human Mu-Opioid Receptor Gene Influences Pain Perception and Patient-Controlled Intravenous Morphine Consumption after Intrathecal Morphine for Postcesarean Analgesia. Anesthesiology. 2008;109:520–526. [PubMed]
  • Skorpen F, Laugsand EA, Klepstad P, Kaasa S. Variable Response to Opioid Treatment: Any Genetic Predictors within Sight? Palliat Med. 2008;22:310–327. [PubMed]
  • Smolka M, Sander T, Schmidt LG, Samochowiec J, Rommelspacher H, Gscheidel N, Wendel B, Hoehe MR. Mu-Opioid Receptor Variants and Dopaminergic Sensitivity in Alcohol Withdrawal. Psychoneuroendocrinology. 1999;24:629–638. [PubMed]
  • Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR. Opiate Receptor Knockout Mice Define Mu Receptor Roles in Endogenous Nociceptive Responses and Morphine-Induced Analgesia. Proc Natl Acad Sci U S A. 1997;94:1544–1549. [PubMed]
  • Sullivan PF, Neale BM, van den Oord E, Miles MF, Neale MC, Bulik CM, Joyce PR, Straub RE, Kendler KS. Candidate Genes for Nicotine Dependence Via Linkage, Epistasis, and Bioinformatics. Am J Med Genet B Neuropsychiatr Genet. 2004;126B:23–36. [PubMed]
  • Szeto CY, Tang NL, Lee DT, Stadlin A. Association between Mu Opioid Receptor Gene Polymorphisms and Chinese Heroin Addicts. Neuroreport. 2001;12:1103–1106. [PubMed]
  • Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT. Ethnicity and Oprm Variant Independently Predict Pain Perception and Patient-Controlled Analgesia Usage for Post-Operative Pain. Mol Pain. 2009;5:32. [PMC free article] [PubMed]
  • Tan EC, Tan CH, Karupathivan U, Yap EP. Mu Opioid Receptor Gene Polymorphisms and Heroin Dependence in Asian Populations. Neuroreport. 2003;14:569–572. [PubMed]
  • Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R, Jr., McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA. Moderators of Naltrexone’s Effects on Drinking, Urge, and Alcohol Effects in Non-Treatment-Seeking Heavy Drinkers in the Natural Environment. Alcohol Clin Exp Res. 2008;32:58–66. [PMC free article] [PubMed]
  • Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, Francis E, Hughes P, Duara R, Mullan M. Association of a Functional Mu-Opioid Receptor Allele (+118a) with Alcohol Dependency. Am J Med Genet. 1999;88:458–461. [PubMed]
  • Vaccarino AL, Kastin AJ. Endogenous Opiates: 1999. Peptides. 2000;21:1975–2034. [PubMed]
  • Vallender EJ, Priddy CM, Chen GL, Miller GM. Human Expression Variation in the Mu-Opioid Receptor Is Paralleled in Rhesus Macaque. Behav Genet. 2008;38:390–395. [PubMed]
  • van den Wildenberg E, Wiers RW, Dessers J, Janssen RG, Lambrichs EH, Smeets HJ, van Breukelen GJ. A Functional Polymorphism of the Mu-Opioid Receptor Gene (Oprm1) Influences Cue-Induced Craving for Alcohol in Male Heavy Drinkers. Alcohol Clin Exp Res. 2007;31:1–10. [PubMed]
  • van der Zwaluw CS, van den Wildenberg E, Wiers RW, Franke B, Buitelaar J, Scholte RH, Engels RC. Polymorphisms in the Mu-Opioid Receptor Gene (Oprm1) and the Implications for Alcohol Dependence in Humans. Pharmacogenomics. 2007;8:1427–1436. [PubMed]
  • Vink JM, Beem AL, Posthuma D, Neale MC, Willemsen G, Kendler KS, Slagboom PE, Boomsma DI. Linkage Analysis of Smoking Initiation and Quantity in Dutch Sibling Pairs. Pharmacogenomics J. 2004;4:274–282. [PubMed]
  • Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the Treatment of Alcohol Dependence. Arch Gen Psychiatry. 1992;49:876–880. [PubMed]
  • Walters CL, Cleck JN, Kuo YC, Blendy JA. Mu-Opioid Receptor and Creb Activation Are Required for Nicotine Reward. Neuron. 2005;46:933–943. [PubMed]
  • Wang D, Quillan JM, Winans K, Lucas JL, Sadee W. Single Nucleotide Polymorphisms in the Human Mu Opioid Receptor Gene Alter Basal G Protein Coupling and Calmodulin Binding. J Biol Chem. 2001;276:34624–34630. [PubMed]
  • Wang Z, Ray R, Faith M, Tang K, Wileyto EP, Detre JA, Lerman C. Nicotine Abstinence-Induced Cerebral Blood Flow Changes by Genotype. Neurosci Lett. 2008;438:275–280. [PMC free article] [PubMed]
  • Way BM, Taylor SE, Eisenberger NI. Variation in the Micro-Opioid Receptor Gene (Oprm1) Is Associated with Dispositional and Neural Sensitivity to Social Rejection. Proc Natl Acad Sci U S A. 2009;106:15079–15084. [PubMed]
  • Wiers RW, Rinck M, Dictus M, van den Wildenberg E. Relatively Strong Automatic Appetitive Action-Tendencies in Male Carriers of the Oprm1 G-Allele. Genes Brain Behav. 2009;8:101–106. [PubMed]
  • Wise RA, Bozarth MA. Brain Mechanisms of Drug Reward and Euphoria. Psychiatr Med. 1985;3:445–460. [PubMed]
  • Xuei X, Flury-Wetherill L, Bierut L, Dick D, Nurnberger J, Jr., Foroud T, Edenberg HJ. The Opioid System in Alcohol and Drug Dependence: Family-Based Association Study. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:877–884. [PubMed]
  • Zadina JE, Hackler L, Ge LJ, Kastin AJ. A Potent and Selective Endogenous Agonist for the Mu-Opiate Receptor. Nature. 1997;386:499–502. [PubMed]
  • Zhang D, Shao C, Shao M, Yan P, Wang Y, Liu Y, Liu W, Lin T, Xie Y, Zhao Y, Lu D, Li Y, Jin L. Effect of Mu-Opioid Receptor Gene Polymorphisms on Heroin-Induced Subjective Responses in a Chinese Population. Biol Psychiatry. 2007;61:1244–1251. [PubMed]
  • Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, Zvartau E, Gelernter J. Association between Two Mu-Opioid Receptor Gene (Oprm1) Haplotype Blocks and Drug or Alcohol Dependence. Hum Mol Genet. 2006a;15:807–819. [PMC free article] [PubMed]
  • Zhang L, Kendler KS, Chen X. The Mu-Opioid Receptor Gene and Smoking Initiation and Nicotine Dependence. Behav Brain Funct. 2006b;2:28. [PMC free article] [PubMed]
  • Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic Expression Imbalance of Human Mu Opioid Receptor (Oprm1) Caused by Variant A118g. J Biol Chem. 2005;280:32618–32624. [PubMed]
  • Zhang Z, Austin SC, Smyth EM. Glycosylation of the Human Prostacyclin Receptor: Role in Ligand Binding and Signal Transduction. Mol Pharmacol. 2001;60:480–487. [PubMed]